Table 3 Immune checkpoints in ECs
From: Immunotherapy in endometrial cancer: rationale, practice and perspectives
Immune checkpoint | Expression | ICBs on trials |
|---|---|---|
PD-1 | T-cell | Pembrolizumab nivolumab |
PD-L1 | Tumor cell | Atezolizumab Avelumab Durvalumab |
CTLA-4 | T-cell | Ipilimumab Tremelimumab |
LAG-3 | T-cell NK cell | INCAGN02385 |
B7-H4 | tumor-associated macrophages Tumor cell | FPA150 |
TIM-3 | T cells, Tregs, B cells, NK cells, DCs and macrophages | NA |